A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and (90)y-labeled rituximab in patients with refractory B-cell lymphoma.

Ola Lindén; Jan Kurkus; Michael Garkavij; Eva Cavallin-Ståhl; Michael Ljungberg; Rune Nilsson; Tomas G Ohlsson; Bengt Sandberg; Sven-Erik Strand; Jan Tennvall

A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and (90)y-labeled rituximab in patients with refractory B-cell lymphoma.

Ola Lindén, Jan Kurkus, Michael Garkavij, Eva Cavallin-Ståhl, Michael Ljungberg, Rune Nilsson, Tomas G Ohlsson, Bengt Sandberg, Sven-Erik Strand, Jan Tennvall

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	457-466
Journal	Cancer Biotherapy & Radiopharmaceuticals
Volume	20
Issue number	4
Publication status	Published - 2005

Subject classification (UKÄ)

Cancer and Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16114994&dopt=Abstract

Cite this

Lindén, O., Kurkus, J., Garkavij, M., Cavallin-Ståhl, E., Ljungberg, M., Nilsson, R., Ohlsson, T. G., Sandberg, B., Strand, S.-E., & Tennvall, J. (2005). A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and (90)y-labeled rituximab in patients with refractory B-cell lymphoma. Cancer Biotherapy & Radiopharmaceuticals, 20(4), 457-466. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16114994&dopt=Abstract

@article{6f2ec2dcefaf43eeb086200ff310f19d,

title = "A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and (90)y-labeled rituximab in patients with refractory B-cell lymphoma.",

author = "Ola Lind{\'e}n and Jan Kurkus and Michael Garkavij and Eva Cavallin-St{\aa}hl and Michael Ljungberg and Rune Nilsson and Ohlsson, {Tomas G} and Bengt Sandberg and Sven-Erik Strand and Jan Tennvall",

year = "2005",

language = "English",

volume = "20",

pages = "457--466",

journal = "Cancer Biotherapy & Radiopharmaceuticals",

issn = "1557-8852",

publisher = "Mary Ann Liebert, Inc.",

number = "4",

}

Lindén, O, Kurkus, J, Garkavij, M, Cavallin-Ståhl, E, Ljungberg, M, Nilsson, R, Ohlsson, TG, Sandberg, B, Strand, S-E & Tennvall, J 2005, 'A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and (90)y-labeled rituximab in patients with refractory B-cell lymphoma.', Cancer Biotherapy & Radiopharmaceuticals, vol. 20, no. 4, pp. 457-466. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16114994&dopt=Abstract>

TY - JOUR

T1 - A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and (90)y-labeled rituximab in patients with refractory B-cell lymphoma.

AU - Lindén, Ola

AU - Kurkus, Jan

AU - Garkavij, Michael

AU - Cavallin-Ståhl, Eva

AU - Ljungberg, Michael

AU - Nilsson, Rune

AU - Ohlsson, Tomas G

AU - Sandberg, Bengt

AU - Strand, Sven-Erik

AU - Tennvall, Jan

PY - 2005

Y1 - 2005

M3 - Article

SN - 1557-8852

VL - 20

SP - 457

EP - 466

JO - Cancer Biotherapy & Radiopharmaceuticals

JF - Cancer Biotherapy & Radiopharmaceuticals

IS - 4

ER -